This is an open-label whole-body PET/CT study for investigating the value of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in patients with Tumor-induced osteomalacia.

Start Date15 Mar 2020

Sponsor / Collaborator

Peking Union Medical College Hospital

NCT03773133 / TerminatedPhase 1/2

A Multicentre, Open-Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

This study consists of two phases. The phase I study is designed to investigate the safety and tolerability of Satoreotide tetraxetan following fractionated i.v. administrations in pre-treated subjects with locally advanced or metastatic cancers expressing sstr2 as identified by Satoreotide trizoxetan Positron Emission Tomography (PET/CT) scans. This phase will encompass both radioactivity escalation and peptide mass dose evaluation. Phase II will assess the efficacy of Satoreotide tetraxetan in subjects in selected indications, in a basket design.

Start Date14 May 2019

Sponsor / Collaborator

Ipsen SA

100 Clinical Results associated with Gallium-68 satoreotide

100 Translational Medicine associated with Gallium-68 satoreotide

100 Patents (Medical) associated with Gallium-68 satoreotide

Literatures (Medical) associated with Gallium-68 satoreotide

01 Oct 2023·Journal of nuclear medicine : official publication, Society of Nuclear Medicine

⁶⁸Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.

Article

Author: Schuler, Martin ; Oezkan, Filiz ; Hautzel, Hubertus ; Darwiche, Kaid ; Stuschke, Martin ; Nader, Michael ; Wienker, Johannes ; Hamacher, Rainer ; Wiesweg, Marcel ; Herrmann, Ken ; Sraieb, Miriam ; Sandach, Patrick ; Eberhardt, Wilfried E E ; Metzenmacher, Martin ; Fendler, Wolfgang P ; Umutlu, Lale ; Kersting, David ; Bölükbas, Servet

PET imaging using the somatostatin receptor 2 (SSTR2) antagonist satoreotide trizoxetan (SSO-120, previously OPS-202) could offer accurate tumor detection and screening for SSTR2-antagonist radionuclide therapy in patients with SSTR2-expressing small cell lung cancer (SCLC). The aim of this single-center study was to investigate tumor uptake and detection rates of ⁶⁸Ga-SSO-120 in comparison to ¹⁸F-FDG PET in the initial staging of SCLC patients. Methods: Patients with newly diagnosed SCLC who underwent additional whole-body ⁶⁸Ga-SSO-120 PET/CT during the initial diagnostic workup were retrospectively included. The mean administered activity was 139 MBq, and the mean uptake time was 60 min. Gold-standard staging ¹⁸F-FDG PET/CT was evaluated if available within 2 wk before or after ⁶⁸Ga-SSO-120 PET if morphologic differences in CT images were absent. ⁶⁸Ga-SSO-120- or ¹⁸F-FDG-positive lesions were reported in 7 anatomic regions (primary tumor, thoracic lymph node metastases, and distant metastases including pleural, contralateral pulmonary, liver, bone, and other) according to the TNM classification for lung cancer (eighth edition). Consensus TNM staging (derived from CT, endobronchial ultrasound-guided transbronchial needle aspiration, PET, and brain MRI) by a clinical tumor board served as the reference standard. Results: Thirty-one patients were included, 12 with limited and 19 with extensive disease according to the Veterans Administration Lung Study Group classification. ⁶⁸Ga-SSO-120-positive tumor was detected in all patients (100%) and in 90 of the 217 evaluated regions (41.5%). Thirteen patients (42.0%) had intense average ⁶⁸Ga-SSO-120 uptake (region-based mean SUV_max ≥ 10); 28 patients (90.3%) had average ⁶⁸Ga-SSO-120 uptake greater than liver uptake (region-based mean peak tumor-to-liver ratio > 1). In 25 patients with evaluable ¹⁸F-FDG PET, primary tumor, thoracic lymph node metastases, and distant metastases were detected in 100%, 92%, and 64%, respectively, of all investigated patients by ⁶⁸Ga-SSO-120 and in 100%, 92%, and 56%, respectively, by ¹⁸F-FDG PET. ⁶⁸Ga-SSO-120 PET detected additional contralateral lymph node, liver, and brain metastases in 1, 1, and 2 patients, respectively (no histopathology available), and ¹⁸F-FDG PET detected additional contralateral lymph node metastases in 3 patients (1 confirmed, 1 systematic endobronchial ultrasound-guided transbronchial needle aspiration-negative, and 1 without available histopathology). None of these differences altered Veterans Administration Lung Study Group staging. The region-based monotonic correlation between ⁶⁸Ga-SSO-120 and ¹⁸F-FDG uptake was low (Spearman ρ = 0.26-0.33). Conclusion: ⁶⁸Ga-SSO-120 PET offers high diagnostic precision with comparable detection rates and additional complementary information to the gold standard, ¹⁸F-FDG PET. Consistent uptake in most patients warrants exploration of SSTR2-directed radionuclide therapy.

01 Mar 2022·Journal of nuclear medicine : official publication, Society of Nuclear MedicineQ1 · MEDICINE

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for ⁶⁸Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Q1 · MEDICINE

Article

Author: Miller, Colin G ; Czernin, Johannes ; Iversen, Peter ; Kjaer, Andreas ; Bahri, Shadfar ; Carlsen, Esben A ; Knigge, Ulrich ; Maffey-Steffan, Johanna ; Virgolini, Irene ; Loft, Mathias ; Grønbæk, Henning ; Powell, Christine ; McEwan, Sandy ; Rohban, Thomas

⁶⁸Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumor (NET) detection and localization. However, the optimal peptide mass and radioactivity ranges for ⁶⁸Ga-satoreotide trizoxetan have not yet been established. We therefore aimed to determine its optimal dosing regimen in patients with metastatic gastroenteropancreatic NETs in a prospective, randomized, 2 × 3 factorial, multicenter phase II study. Methods: Patients received ⁶⁸Ga-satoreotide trizoxetan at a peptide mass of 5-20 µg on day 1 of the study and of 30-45 µg on days 16-22, at 1 of 3 ⁶⁸Ga radioactivity ranges (40-80, 100-140, or 160-200 MBq). Whole-body PET/CT imaging was performed 50-70 min after each injection. The primary endpoint was the detection rate of NET lesions imaged by ⁶⁸Ga-satoreotide trizoxetan relative to contrast-enhanced CT (for each of the 6 peptide mass and radioactivity range combinations). Results: Twenty-four patients were evaluated in the per-protocol analysis. The median number of lesions detected by ⁶⁸Ga-satoreotide trizoxetan PET/CT or PET alone was at least twice as high as the number detected by contrast-enhanced CT across the 6 studied peptide mass and radioactivity range combinations. There were no differences between the 2 peptide mass ranges or between the 3 radioactivity ranges in the number of identified lesions. However, a trend toward a lower relative lesion count was noted in the liver for the 40- to 80-MBq range. No relationship was observed between the radioactivity range per patient's body weight (MBq/kg) and the number of lesions detected by ⁶⁸Ga-satoreotide trizoxetan. The median diagnostic sensitivity of ⁶⁸Ga-satoreotide trizoxetan PET/CT, based on the number of lesions per patient, ranged from 85% to 87% across the different peptide mass and radioactivity ranges. Almost all reported adverse events were mild and self-limiting. Conclusion: A radioactivity of 100-200 MBq with a peptide mass of up to 50 µg was confirmed as the optimal dosing regimen for ⁶⁸Ga-satoreotide trizoxetan to be used in future phase III studies.

01 Jan 2022·Frontiers in Oncology

Head-to-Head Comparison of ⁶⁸Ga-DOTA-TATE and ⁶⁸Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study.

Article

Author: Liu, Yu ; Li, Fang ; Wang, Peipei ; Huo, Li ; Hou, Guozhu ; Xing, Xiaoping ; Xia, Weibo ; Zhang, Yuwei ; Jing, Hongli

Background:

The purpose of this study is to compare the sensitivity of ⁶⁸Ga-DOTA-JR11 and ⁶⁸Ga-DOTA-TATE PET/CT for detecting the responsible tumor of tumor-induced osteomalacia (TIO) and investigate if ⁶⁸Ga-DOTA-JR11 PET/CT can identify the culprit tumor of TIO in multiple suspicious lesions in ⁶⁸Ga-DOTA-TATE PET/CT.

Methods:

A total of 19 patients with suspected TIO were prospectively recruited in this study. Each patient underwent whole-body PET/CT scan 40-60 min postinjection using ⁶⁸Ga-DOTA-TATE and ⁶⁸Ga-DOTA-JR11 on the same PET/CT, respectively in sequence, and on consecutive days. The diagnosis of TIO was confirmed by the combination of the postsurgical pathological results of the tumor and clinical information.

Results:

Among the 19 patients with TIO who were included in this study, culprit tumors from all patients were confirmed pathologically. ⁶⁸Ga-DOTA-TATE PET/CT positively identified the causative tumor in 18/19 patients, whereas ⁶⁸Ga-DOTA-JR11 PET/CT was positive in 11/19 patients (94.7% vs. 57.9%, respectively; p < 0.05). ⁶⁸Ga-DOTA-TATE PET/CT demonstrated more than one increased focal activity in 7 patients for a total of 16 lesions (3 lesions each in 2 patients and 2 lesions each in the rest 5 patients). However, seven of these 16 lesions showed concordant results on ⁶⁸Ga-DOTA-JR11 PET/CT by demonstrating increased activity (one lesion in each of the 7 patients). The surgical specimens of the lesions in these 7 patients confirmed the phosphaturic mesenchymal tumor. A total of 11 culprit tumors were positive in both ⁶⁸Ga-DOTA-TATE and ⁶⁸Ga-DOTA-JR11 PET/CT. The SUVmax of 11 culprit tumors was significantly higher on ⁶⁸Ga-DOTA-TATE PET/CT compared with that on ⁶⁸Ga-DOTA-JR11 PET/CT (17.8 ± 12.5 vs. 6.8 ± 6.2; p < 0.05).

Conclusions:

⁶⁸Ga-DOTA-TATE PET/CT is more sensitive to ⁶⁸Ga-DOTA-JR11 PET/CT in the detection of the culprit tumor of TIO. However, ⁶⁸Ga-DOTA-JR11 PET/CT might be helpful to identify the tumor in multiple suspicious lesions in ⁶⁸Ga-DOTA-TATE PET/CT.

Clinical Trial Registration:

clinicaltrials.gov, identifier NCT04689893.

News (Medical) associated with Gallium-68 satoreotide

07 Sep 2023

·www.prnewswire.com

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

Ariceum develops satoreotide its first and best-in-class somatostatin receptor 2 antagonist in extensive stage small cell lung cancer Phase Ib study design will be presented at the European Association of Nuclear Medicine Congress 2023 (EANM 2023) in Vienna, Austria on 10th September 2023 BERLIN, Sept. 7, 2023 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce that the first patient has been dosed with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC), at the Murdoch University Health Center in Perth, Australia. Ariceum has successfully initiated its multicentre, open label Phase Ib study which will investigate the safety and tolerability of the 'theranostic pair' of somatostatin receptor antagonist 68Ga-Satoreotide Trizoxetan (SSO120) and 177Lu-satoreotide tetraxetan (SSO110) in patients with ES-SCLC. The main objective of the study is to establish a recommended Phase 2 dose and schedule. 'Theranostics' is the approach of using two paired drugs – the first, a diagnostic agent to identify cells which exhibit a particular biomarker; and the second, a therapeutic drug, to act on those cells. Both the diagnostic agent and therapeutic drug contain Ariceum's proprietary peptide satoreotide, a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SST2), a cell surface protein often overexpressed in certain cancers including small cell lung cancer (SCLC). The study, entitled LuSato-1 study, includes patients with ES-SCLC who will each receive an infusion containing the diagnostic imaging agent, somatostatin receptor antagonist before undergoing a positron emission tomography (PET) scan. This will determine if a patient's tumours express the SST2. Patients identified with confirmed SST2 expression will receive escalating doses of satoreotide, in addition to the immunotherapy atezolizumab, a PD-L1 checkpoint inhibitor, during the maintenance phase of their treatment until a recommended phase 2 dose can be defined. Additional patients may be enrolled in an expansion cohort. Further details on the study can be found on Australian Clinical Trials, under identifier Ariceum SSO11O-01. Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: "The initiation of this Phase Ib study is an important milestone reached by the Company in close collaboration with our partners in Australia and Europe. We believe that our lead targeted systemic radiopharmaceutical product satoreotide has the potential to demonstrate positive results in patients with extensive stage small cell lung cancer. Theranostics holds great hope as a highly targeted form of cancer therapy, using a 'search and destroy' approach to seek out tumours while sparing healthy tissue." Germo Gericke, Chief Medical Officer of Ariceum Therapeutics, said: "Although immune checkpoint blockade has improved the treatment of ES-SCLC, disease recurrence often occurs early in the maintenance phase. Adding targeted radiotherapy with satoreotide to immune checkpoint blockade in the maintenance setting holds the promise to improve the therapeutic effect of the maintenance therapy." An Abstract on the LuSato-1 study will be presented at the European Association of Nuclear Medicine Congress 2023 (EANM 2023) in Vienna, Austria, on 10th September 2023. Presentation details below. Abstract OP-230 Top Rated Oral Presentations (TROP) Session: Oncology & Theranostics Committee Session: 606 - Neuroendocrine Tumours Treatment Abstract title: A phase I theranostic study evaluating the safety and tolerability of 177Lu-satoreotide tetraxetan with 68Ga-satoreotide trizoxetan companion imaging in participants with extensive-stage small-cell lung cancer (ES-SCLC) on atezolizumab maintenance therapy Authors: L. Emmett, J. Cardaci, K. O'Byrne, S. Arulananda, A. Prawira, B. Pais, M. Crumbaker, N. Lenzo Date & Time: 10 September, 4:45-6:15pm CEST Notes to Editors About Ariceum Therapeutics Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of 'Marie Curie' whose discovery of radium and polonium have been huge contributions to finding treatments for cancer. Ariceum's lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (SST2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a 'theranostic' pair for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum Therapeutics, launched in 2021, acquired all rights from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Australia, United Kingdom, United States of America and Switzerland and activities currently across the globe. Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit SOURCE Ariceum Therapeutics

Phase 1OligonucleotideAcquisition

100 Deals associated with Gallium-68 satoreotide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Small Cell Lung Cancer	Phase 2	US	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	AT	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	BE	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	FR	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	DE	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	CH	Ipsen SA	14 May 2019
Small Cell Lung Cancer	Phase 2	GB	Ipsen SA	14 May 2019
Breast Cancer	Phase 2	AT	Ipsen SA	22 Oct 2018
Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 2	US	Ipsen SA	26 Sep 2017
Gastro-Enteropancreatic Neuroendocrine Tumor	Phase 2	AT	Ipsen SA	26 Sep 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SNMMI2024	Not Applicable	Lung Cancer	-	68Ga]Ga-satoreotide trizoxetan (SCLC patients)	utcknrbopo(rytinxdvcw) = oyxjipitof csnmqtfsdc (mdepcpuysk )	-	09 Jun 2024
SNMMI2023	Not Applicable	Small Cell Lung Cancer	-	68Ga-SSO-12068Ga-Satoreotide (68Ga-SSO-120 PET/CT)	qsblvwnuho(tdzferwuny) = pkbhkwibtm xfyipbuiti (kskvxjhinz ) View more	-	28 Aug 2023
				FDG68Ga-Satoreotide (FDG PET/CT)	jquqkrdhjb(flyjwdwppj) = nomcsijnib pergazjpau (vwsqefxusf ) View more
NCT04689893 (Pubmed \| Front Oncol) Manual	Phase 1	Oncogenic Osteomalacia	19	68Ga-DOTA-TATE	hawgsxwkms(ndatuejnyf) = xcwoukstmn dwioomtcul (jyhyqmcmyd )	Positive	24 Feb 2022
				Gallium-68 satoreotide	hawgsxwkms(ndatuejnyf) = butvstxkis dwioomtcul (jyhyqmcmyd )
NCT03220217 (Pubmed \| J Nucl Med) Manual	Phase 2	Neuroendocrine Tumors	24	Gallium-68 satoreotide trizoxetan	zectpbgjvz(ssxpyhfrlc) = Gallium-68 satoreotide trizoxetan PET/CT or PET alone was at least twice as high as the number detected by contrast-enhanced CT jaeikmygyx (lgtqmlpkmx )	Positive	02 Jul 2021
				contrast-enhanced CT
NCT03697551 (CTgov)	Phase 2	Breast Cancer	4	68Ga-Satoreotide Trizoxetan	vmjdperxhq(kloarznmpk) = ntpryxfgsr vbvbhapyub (vliawdpomm, qbikvojxsm - nkkmtprbsk) View more	-	07 Sep 2020
NCT02162446 (CTgov)	Phase 1/2	SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	12	OPS202 peptide+68Ga-OPS202+68Ga (All Participants)	tcyetgbztk(efoyfmfrdf) = ggeieupiqi giufmrapoo (aagjmysixb, hfqdhcxhnx - emkglcpxvo) View more	-	02 Oct 2019
				IP (ITT Population (Pre-dose))	pjvhhgrumj(xehqbfogvl) = jddcnbuwom wvtdpillio (awrlcdhhfz, gtcdiawzec - osjbknktux) View more
EANM2017	Not Applicable	Neuroendocrine Tumors SSTR2	19	177 Lu-OPS201	gzzkvixrgq(zvwqfeyuae) = tdyenkyvfd ypnfzvlesi (fbqothtwdl )	Positive	11 Sep 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis